Literature DB >> 17456522

Statistical design of THRio: a phased implementation clinic-randomized study of a tuberculosis preventive therapy intervention.

Lawrence H Moulton1, Jonathan E Golub, Betina Durovni, Solange C Cavalcante, Antonio G Pacheco, Valeria Saraceni, Bonnie King, Richard E Chaisson.   

Abstract

BACKGROUND: Tuberculosis (TB) is a major public health problem in Rio de Janeiro, where a high proportion of HIV-infected adults are co-infected with latent TB. Health officials in Brazil have recommended that HIV patients be tested for TB infection and given TB prophylaxis (isoniazid) if positive. In practice, although Brazil is a model for provision of antiretroviral therapy to patients with advanced HIV disease, relatively few such patients receive TB testing and prevention services.
PURPOSE: We initiated a randomized study of a health services intervention to train health personnel in implementation of the recommended routine of TB testing and isoniazid prophylaxis. The primary goal is to reduce incident TB disease in the HIV clinic population.
METHODS: The clinic-level intervention will be phased in gradually over the study period until all clinics have received the intervention. The clinics' order of initiation of intervention was randomized and subjected to constraints based on clinic-level covariates. This phased intervention cluster-randomized trial required special attention to power/sample size calculation and randomization procedures, of which we provide the relevant details.
RESULTS: Special design considerations accounted for within-clinic correlation, variation in the clinic size, time-varying ratio of intervention to control clinics and guaranteed post-randomization covariate balance. These were successfully implemented for the estimation of power and execution of the randomization strategy. LIMITATIONS: Although the design features of randomization by clinic and phased implementation of the intervention meet logistic and local needs, they substantially lower the statistical power of the study.
CONCLUSIONS: Studies with cluster-randomized order of intervention introduction can provide useful information on intervention effects. Their design and analysis are more complicated than for individually randomized parallel design trials. The methods we describe represent practical approaches to the challenges raised in the course of designing this study.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17456522     DOI: 10.1177/1740774507076937

Source DB:  PubMed          Journal:  Clin Trials        ISSN: 1740-7745            Impact factor:   2.486


  43 in total

1.  Estimating the extent of underreporting of mortality among HIV-infected individuals in Rio de Janeiro, Brazil.

Authors:  Antonio G Pacheco; Valeria Saraceni; Suely H Tuboi; Lilian M Lauria; Lawrence H Moulton; José Cláudio Faulhaber; Bonnie King; Jonathan E Golub; Betina Durovni; Solange Cavalcante; Lee H Harrison; Richard E Chaisson; Mauro Schechter
Journal:  AIDS Res Hum Retroviruses       Date:  2010-10-07       Impact factor: 2.205

2.  Long-term protection from isoniazid preventive therapy for tuberculosis in HIV-infected patients in a medium-burden tuberculosis setting: the TB/HIV in Rio (THRio) study.

Authors:  Jonathan E Golub; Silvia Cohn; Valeria Saraceni; Solange C Cavalcante; Antonio G Pacheco; Lawrence H Moulton; Betina Durovni; Richard E Chaisson
Journal:  Clin Infect Dis       Date:  2014-11-02       Impact factor: 9.079

3.  The implementation of isoniazid preventive therapy in HIV clinics: the experience from the TB/HIV in Rio (THRio) study.

Authors:  Betina Durovni; Solange C Cavalcante; Valeria Saraceni; Vitoria Vellozo; Giselle Israel; Bonnie S King; Silvia Cohn; Anne Efron; Antonio G Pacheco; Lawrence H Moulton; Richard E Chaisson; Jonathan E Golub
Journal:  AIDS       Date:  2010-11       Impact factor: 4.177

4.  Impact of isoniazid preventive therapy for HIV-infected adults in Rio de Janeiro, Brazil: an epidemiological model.

Authors:  David W Dowdy; Jonathan E Golub; Valeria Saraceni; Lawrence H Moulton; Solange C Cavalcante; Silvia Cohn; Antonio G Pacheco; Richard E Chaisson; Betina Durovni
Journal:  J Acquir Immune Defic Syndr       Date:  2014-08-15       Impact factor: 3.731

5.  Finite-sample corrected generalized estimating equation of population average treatment effects in stepped wedge cluster randomized trials.

Authors:  JoAnna M Scott; Allan deCamp; Michal Juraska; Michael P Fay; Peter B Gilbert
Journal:  Stat Methods Med Res       Date:  2014-09-29       Impact factor: 3.021

Review 6.  Review of Recent Methodological Developments in Group-Randomized Trials: Part 1-Design.

Authors:  Elizabeth L Turner; Fan Li; John A Gallis; Melanie Prague; David M Murray
Journal:  Am J Public Health       Date:  2017-04-20       Impact factor: 9.308

7.  Parental Choice of Recall Method for HPV Vaccination: A Pragmatic Trial.

Authors:  Allison Kempe; Sean T O'Leary; Jo Ann Shoup; Shannon Stokley; Steven Lockhart; Anna Furniss; L Miriam Dickinson; Juliana Barnard; Matthew F Daley
Journal:  Pediatrics       Date:  2016-02-26       Impact factor: 7.124

8.  Sample size determinations for stepped-wedge clinical trials from a three-level data hierarchy perspective.

Authors:  Moonseong Heo; Namhee Kim; Michael L Rinke; Judith Wylie-Rosett
Journal:  Stat Methods Med Res       Date:  2016-03-17       Impact factor: 3.021

Review 9.  Measuring improvement in populations: implementing and evaluating successful change in lung cancer care.

Authors:  Xinhua Yu; Lisa M Klesges; Mathew P Smeltzer; Raymond U Osarogiagbon
Journal:  Transl Lung Cancer Res       Date:  2015-08

10.  Prevalent tuberculosis at HIV diagnosis in Rio de Janeiro, Brazil: the TB/HIV in Rio (THRio) Cohort.

Authors:  Valeria Saraceni; Silvia Cohn; Solange C Cavalcante; Antonio G F Pacheco; Lawrence H Moulton; Richard E Chaisson; Betina Durovni; Jonathan E Golub
Journal:  J Acquir Immune Defic Syndr       Date:  2014-09-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.